Protective effect of ginsenosides Rg1 and Re on lipopolysaccharide-induced sepsis by competitive binding to toll-like receptor 4

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5654-5663

  Su, Fei ^a   Xue, Yin ^a   Wang, Yuemin ^a   Zhang, Lili ^a   Chen, Wangxue ^b   Hu, Songhua ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GINSENOSIDE RE; GINSENOSIDE RG 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTECTIVE AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; GINSENOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISEPSIS; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; FEVER; GENE EXPRESSION; GENE MUTATION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDE-INDUCED SEPSIS; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMICALLY INDUCED; METABOLISM; SEPSIS; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; CYCLOOXYGENASE 2; GINSENOSIDES; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 84940944912     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01381-15     Document Type: Article

References (43)

1. Song R, Kim J, Yu D, Park C, Park J. 2012. Kinetics of IL-6 and TNF-alpha changes in a canine model of sepsis induced by endotoxin. Vet Immunol Immunopathol 146:143-149. http://dx.doi.org/10.1016/j.vetimm.2012.02.008.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310. http://dx.doi.org/10.1097/00003246-200107000-00002.
3. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170. http://dx.doi.org/10.1038/72262.
4. Lee SK, Kim SD, Lee HY, Baek SH, Ko MJ, Son BG, Park S, Choi YW, Bae YS 2012. α-Iso-cubebene, a natural compound isolated from Schisandra chinensis fruit, has therapeutic benefit against polymicrobial sepsis. Biochem Biophys Res Commun 426:226-231. http://dx.doi.org/10.1016/j.bbrc.2012.08.070.
5. Ohto U, Fukase K, Miyake K, Shimizu T. 2012. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci U S A 109:7421-7426. http://dx.doi.org/10.1073/pnas.1201193109.
6. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG 2003. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187:631-639. http://dx.doi.org/10.1086/367990.
7. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088. http://dx.doi.org/10.1126/science.282.5396.2085.
8. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672.
9. Farrow B, Evers BM 2002. Inflammation and the development of pancreatic cancer. Surg Oncol 10:153-169. http://dx.doi.org/10.1016/S0960-7404(02)00015-4.
10. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481:243-268.
11. Beutler B. 2000. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12:20-26. http://dx.doi.org/10.1016/S0952-7915(99)00046-1.
12. Hawkins LD, Christ WJ, Rossignol DP 2004. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 4:1147-1171. http://dx.doi.org/10.2174/1568026043388123.
13. Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, Ii M. 2009. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 157:1250-1262. http://dx.doi.org/10.1111/j.1476-5381.2009.00297.x.
14. Lian LH, Jin Q, Song SZ, Wu YL, Bai T, Jiang S, Li Q, Yang N, Nan JX 2013. Ginsenoside Rh2 downregulates LPS-induced NF-kappa B activation through inhibition of TAK1 phosphorylation in RAW 264.7 murine macrophage. Evid Based Complement Alternat Med 2013:646728.
15. Hu S, Concha C, Lin F, Persson WK 2003. Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol 91:29-37. http://dx.doi.org/10.1016/S0165-2427(02)00264-7.
16. Rivera E, Daggfeldt A, Hu S. 2003. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 91:19-27. http://dx.doi.org/10.1016/S0165-2427(02)00269-6.
17. Song X, Chen J, Sakwiwatkul K, Li R, Hu S. 2010. Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re. Int Immunopharmacol 10:351-356. http://dx.doi.org/10.1016/j.intimp.2009.12.009.
18. Sun J, Song X, Hu S. 2008. Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice. Clin Vaccine Immunol 15:303-307. http://dx.doi.org/10.1128/CVI.00448-07.
19. Xiang YZ, Shang HC, Gao XM, Zhang BL 2008. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res 22:851-858. http://dx.doi.org/10.1002/ptr.2384.
20. Su F, Yuan L, Zhang L, Hu S. 2012. Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway. Vaccine 30:4106-4112. http://dx.doi.org/10.1016/j.vaccine.2012.03.052.
21. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT 2003. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF.J Exp Med 198:1043-1055. http://dx.doi.org/10.1084/jem.20031023.
22. Fukuda N, Tanaka H, Shoyama Y. 2000. Formation of monoclonal antibody against a major ginseng component, ginsenoside Rg1 and its characterization. Monoclonal antibody for a ginseng saponin. Cytotechnology 34:197-204.
23. Livak KJ, Schmittgen TD 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
24. Katritzky AR, Kuanar M, Slavov S, Hall CD, Karelson M, Kahn I, Dobchev DA 2010. Quantitative correlation of physical and chemical properties with chemical structure: utility for prediction. Chem Rev 110: 5714-5789. http://dx.doi.org/10.1021/cr900238d.
25. Mannhold R, Poda GI, Ostermann C, Tetko IV 2009. Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds. J Pharm Sci 98:861-893. http://dx.doi.org/10.1002/jps.21494.
26. Wildman SA, Crippen GM 1999. Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci 39:868-873. http://dx.doi.org/10.1021/ci990307l.
27. Hussey SE, Liang H, Costford SR, Klip A, DeFronzo RA, Sanchez-Avila A, Ely B, Musi N. 2013. TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells. Biosci Rep 33:37-47.
28. Walter A, Gutknecht J. 1986. Permeability of small nonelectrolytes through lipid bilayer membranes. JMembr Biol 90:207-217. http://dx.doi.org/10.1007/BF01870127.
29. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554. http://dx.doi.org/10.1056/NEJMoa022139.
30. Blackwell TS, Christman JW 1996. Sepsis and cytokines: current status. Br J Anaesth 77:110-117. http://dx.doi.org/10.1093/bja/77.1.110.
31. Fisher CJ, Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843.
32. Abraham J, Lewis G. 1998. Secrecy and transparency of medicines licensing in the EU. Lancet 352:480-482. http://dx.doi.org/10.1016/S0140-6736(97)11282-X.
33. Jerala R. 2007. Structural biology of the LPS recognition. Int J Med Microbiol 297:353-363. http://dx.doi.org/10.1016/j.ijmm.2007.04.001.
34. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433. http://dx.doi.org/10.1126/science.1698311.
35. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ 1990. Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431. http://dx.doi.org/10.1126/science.2402637.
36. Gegner JA, Ulevitch RJ, Tobias PS 1995. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 270:5320-5325.
37. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189:1777-1782. http://dx.doi.org/10.1084/jem.189.11.1777.
38. Bremner P, Heinrich M. 2002. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54:453-472. http://dx.doi.org/10.1211/0022357021778637.
39. Lehr HA, Bittinger F, Kirkpatrick CJ 2000. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J Pathol 190:373-386. http://dx.doi.org/10.1002/(SICI)1096-9896(200002)190:3<373::AID-PATH593>3.0.CO;2-3.
40. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891. http://dx.doi.org/10.1038/nature01326.
41. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. 2003. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 24:254-258. http://dx.doi.org/10.1016/S1471-4906(03)00079-6.
42. Riedemann NC, Guo RF, Ward PA 2003. Novel strategies for the treatment of sepsis. Nat Med 9:517-524. http://dx.doi.org/10.1038/nm0503-517.
43. Kimura A, Kishimoto T. 2010. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40:1830-1835. http://dx.doi.org/10.1002/eji.201040391.